The Brazil Tariff Is Not a Yes or No Question: A Practical Guide for Pharmaceutical and Medical Product Importers

On July 15, 2026, the Office of the U.S. Trade Representative issued its final Section 301 action on Brazil. The action imposes an additional 25% duty on covered Brazilian origin goods entered for consumption, or withdrawn from warehouse for consumption, at or after 12:01 a.m. Eastern time on July 22, 2026. Certain products are exempt from the additional duty.

For pharmaceutical, biotech, and medical product importers with any exposure to Brazilian sourcing, this is not a straightforward yes or no situation. The tariff applies to some Brazilian goods and not others, the exemption list is specific rather than blanket, and timing around the July 22 effective date can change how a given shipment is treated. This guide walks through what importers need to verify before assuming they know how a Brazilian shipment will be treated.

The Core Mistake to Avoid: A shipper cannot safely conclude that all Brazilian pharmaceutical products are exempt, or that every shipment from Brazil now carries an additional 25% duty. Both statements are too broad. Coverage depends on the specific HTS provision, and for certain chemicals, on their pharmaceutical application.

1. Why Origin and Shipping Country Are Not Always the Same

Several structural factors have made India the dominant beneficiary of pharmaceutical sourcing diversification away from China:

The Section 301 action applies based on the customs country of origin of the goods, not the country from which the shipment was sent. A product manufactured in a third country and merely transshipped through Brazil does not become subject to this tariff by virtue of the shipping route. Conversely, a product genuinely manufactured or substantially transformed in Brazil is covered regardless of where it is shipped from.

Importers should confirm country of origin through the same substantial transformation analysis CBP applies elsewhere. Country of origin marking on the product and commercial invoice description are starting points, but the underlying manufacturing history is what actually controls.

The first verification step is not what the invoice says. It is where the actual manufacturing or substantial transformation took place.

2. How Chapter 99 Classifications Work With the Ordinary HTS Code

Section 301 tariffs are implemented through a secondary classification system. The product retains its ordinary Harmonized Tariff Schedule classification, the code that determines the base duty rate and regulatory treatment, and a Chapter 99 provision is added to the entry to reflect the additional Section 301 duty.

This means an importer needs two pieces of information for every affected shipment: the standard HTS classification for the product itself, and the applicable Chapter 99 secondary classification that reflects the Brazil action. Filing an entry with only the primary HTS code, without evaluating whether a Chapter 99 provision applies, risks an inaccurate entry regardless of whether the omission increases or decreases the duty paid.

3. Pharmaceutical Exemptions Versus Blanket Industry Exemptions

USTR expanded the final exemption list to include additional pharmaceuticals and pharmaceutical ingredients. This is a meaningful update for life sciences importers, but it should not be read as a general healthcare exemption.

The exemption operates at the level of the specific HTS provision. A product classified under an HTS code that appears on the exemption annex is excluded from the additional duty. A product that is pharmaceutical in a general commercial sense, but whose HTS classification does not appear on the annex, is not automatically covered simply because it is used in a healthcare context.

Practically, this means every product in a Brazilian pharmaceutical or medical device supply chain needs to be checked individually against the exemption annex by its specific HTS number. Assuming coverage because a related product, or a product in the same general category, is exempt is a common and avoidable error.

4. Why Intended Use May Matter for Chemical Ingredients

For certain chemical products, exemption eligibility depends not only on the HTS classification but on the chemical’s actual pharmaceutical application. A chemical compound that has both pharmaceutical and non-pharmaceutical industrial uses may be classified under a provision where exemption coverage is conditioned on the specific end use of the imported merchandise.

This creates a documentation obligation that goes beyond the customs entry itself. Importers relying on a pharmaceutical use exemption for this category of chemical inputs should be prepared to demonstrate that the specific shipment in question is, in fact, being imported for pharmaceutical application, not simply that the chemical is capable of pharmaceutical use in general.

5. Treatment of In Transit, Bonded, and Foreign Trade Zone Merchandise

The USTR notice includes a limited in transit provision for qualifying goods. Goods loaded for shipment before July 22, 2026 and entered before July 29, 2026 may qualify for treatment under this provision, avoiding the additional duty despite entering after the effective date. Importers with shipments currently in transit from Brazil should confirm loading dates and expected entry dates against this window immediately.

Goods subject to the tariff that are admitted to a U.S. foreign trade zone generally must enter under privileged foreign status, unless the goods are eligible for domestic status. This status election has consequences for how and when duty is ultimately assessed, and importers using FTZ warehousing for Brazilian origin product should confirm the correct status designation with their customs broker before the July 22 effective date.

The practical point for anyone managing Brazilian origin shipments right now: entry timing matters as much as the underlying product. A shipment arriving at a U.S. port near July 22 could receive materially different tariff treatment depending on precisely when it is entered, or when it is withdrawn from a bonded warehouse, not simply on when it left Brazil.

6. Documents Importers Should Retain to Support Exemption Claims

For any Brazilian origin product claimed as exempt, particularly pharmaceutical products and chemical ingredients where end use matters, importers should maintain documentation sufficient to support that claim in the event of a CBP request for information or an audit. Relevant records include:

• Certificates of analysis or product specification sheets confirming the product’s chemical identity and classification
• Purchase orders and commercial invoices that clearly describe the pharmaceutical application or end use of the shipment
• Manufacturing and substantial transformation records supporting the claimed country of origin
• Correspondence with the supplier confirming the intended use of chemical inputs where end use affects exemption eligibility
• Bills of lading and loading documentation for any shipment relying on the in transit provision

7. When to Request a Binding Classification Ruling

For products where the HTS classification is genuinely unclear, or where the exemption annex language does not map cleanly onto the specific product at issue, a binding ruling request to CBP provides a legally authoritative determination. This is worth pursuing for high volume products, high value shipments, or product lines where the classification question will recur across many future entries.

A binding ruling takes time to obtain and is not a solution for a shipment already in transit before July 22. But for importers with an ongoing Brazilian supply relationship, requesting rulings now on the products where classification is genuinely ambiguous protects against inconsistent treatment across future entries and reduces audit exposure.

Immediate Action Checklist

For any importer with current or planned Brazilian origin shipments, the following steps should be completed before July 22, 2026 wherever possible, and immediately thereafter for any shipment already in transit.

1. Confirm the product’s HTS classification.
2. Confirm that Brazil is the customs country of origin, not simply the country of shipment.
3. Identify the applicable Chapter 99 secondary classification.
4. Check whether the exact HTS provision appears in an exemption annex.
5. Preserve documentation supporting pharmaceutical end use where relevant.
6. Review goods already in transit, in bonded warehouses, or in foreign trade zones.
7. Recalculate landed cost before authorizing new shipments.

How Euro-American Worldwide Logistics Supports Brazil Tariff Compliance

Euro-American Worldwide Logistics operates a licensed in-house U.S. Customs Brokerage with specific expertise in pharmaceutical and medical product classification. Our brokerage team can review your Brazilian origin product portfolio against the Section 301 action and the exemption annexes, confirm the applicable Chapter 99 provisions, and assess whether shipments currently in transit qualify for relief under the in transit provision.

For life sciences importers relying on the pharmaceutical exemption for chemical ingredients with dual use applications, we can help establish the documentation practices needed to support that position if CBP requests evidence of end use.

If you have Brazilian origin shipments affected by this action, particularly any currently in transit or held in a bonded warehouse or foreign trade zone, contact our team today.

---

This article reflects the USTR Federal Register notice issued July 15, 2026. Tariff treatment for specific products should be confirmed with a licensed customs broker before entry.